SCHEMBL3370228

SCHEMBL3370228

CNC(=O)/C(=N/OC)c1ccccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
TSHR P16473 2/20 0.51
KDM4E B2RXH2 6/20 0.42
HPGD P15428 6/20 0.42
ALDH1A1 P00352 3/20 0.42
HIF1A Q16665 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MPO P05164 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 2/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
HMGB1 P09429 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
NAPRT Q6XQN6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370230 1.00 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL5195934 1.00 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL7745166 0.86 TSHR (0.41) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL8846269 0.84 NPC1 (0.41) LMNAKDM4EHPGDALDH1A1HIF1A
SCHEMBL8846279 0.84 NPC1 (0.41) LMNAKDM4EHPGDALDH1A1HIF1A
SCHEMBL6705432 0.83 LMNA (0.55) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL7119395 0.83 LMNA (0.55) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6705433 0.83 LMNA (0.55) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL8761028 0.83 SIRT2 (0.38) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL7221644 0.82 LMNA (0.42) LMNATSHRKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268446-B1 METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-10-06 EP disclosed
CN-1280278-C Method for producing asymmetrical 4,6-bis (aryloxy) pyrimidine derivatives BAYER AG (DE) 2006-10-18 CN disclosed
CN-1618792-A Method of producing methoxyimino acetic amide BAYER AG (DE) 2005-05-25 CN disclosed
CN-1537096-A Method for producing (2E)-2-(hydroxyphenyl)-2-(alkoxyimino)-N-methylacetamides �ݶ�ũ�����ѧ�ɷݹ�˾ 2004-10-13 CN disclosed
US-20040186318-A1 Method for producing (2e)-2-(hydroxyphenyl-2-(alkoxyimino)-n-methylacetamides BAYER CROPSCIENCE AG (DE) 2004-09-23 US disclosed
CN-1160313-C Process for preparing methoxyiminoacetamide 2004-08-04 CN disclosed
US-6734304-B2 REACTING THE CORRESPONDING 4.6-DIHALOPYRIMIDINE COMPOUND WITH BASE; ONE POT PROCESS BAYER AKTIENGESELLSCHAFT (DE) 2004-05-11 US disclosed
EP-1414789-A1 METHOD FOR PRODUCING (2E)-2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDES Bayer CropScience AG (DE) 2004-05-06 EP disclosed
US-6660872-B1 In high yields BAYER AKTIENGESELLSCHAFT (DE) 2003-12-09 US disclosed
CN-1419549-A Method for producing asymmetrical 4,6-bis (aryloxy) pyrimidine derivatives BAYER AG (DE) 2003-05-21 CN disclosed
US-20030092723-A1 Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2003-05-15 US disclosed
WO-2003014065-A1 METHOD FOR PRODUCING (2E)-2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDES BAYER CROPSCIENCE AG (DE) 2003-02-20 WO disclosed
EP-1268446-A1 METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES Bayer CropScience AG (DE) 2003-01-02 EP disclosed
CN-1351585-A Process for preparing methoxyiminoacetamide BAYER AG (DE) 2002-05-29 CN disclosed
WO-2001072719-A1 METHOD FOR PRODUCING ASYMMETRICAL 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed
US-6114363-A ACTIVITY AGAINST A BROAD SPECTRUM OF PHYTOPATHOGENIC FUNGI; COMPOUNDS SUCH AS N-METHYL-E-2-METHOXYIMINO-2-((2-(3-CHLORO-5-(PROP-1-EN-3-OXIMINOETH-1' -YL)PYRIDIN-2-YL))OXYMETHYL) PHENYL)ACETAMIDE BASF AKTIENGESELLSCHAFT (DE) 2000-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186318-A1 Method for producing (2e)-2-(hydroxyphenyl-2-(alkoxyimino)-n-methylacetamides HMOX2, CYP1A2, PTGS2 LMNA 1227/4885TSHR 4445/4885KDM4E 1620/4885
US-20030092723-A1 Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives DPYD, TYMS, TYMP LMNA 4551/4885TSHR 3130/4885KDM4E 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.